Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

ABSTRACT: Most patients with diffuse large B-cell lymphoma (DLBCL) are diagnosed at age 60 years or older. Challenges to effective therapy among older individuals include unfavorable biologic features of DLBCL, geriatric vulnerabilities, suboptimal treatment selection, and toxicities of cytotoxic chemotherapy. Wider application of geriatric assessments may help identify fit older patients who benefit from standard immunochemotherapy without unnecessary dose reductions. Conversely, attenuated regimens may provide a better balance of risk and benefit for selected unfit or frail patients. Supportive care with the use of corticosteroid-based prephase, prophylactic growth factors, and early institution of supportive and palliative care can help maximize treatment tolerance. Several novel or emerging ther

SUBMITTER: Di M 

PROVIDER: S-EPMC7873335 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature